Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that recruit an E3 ligase to a target protein to facilitate ubiquitination and subsequent degradation of that protein. While the field of targeted degraders is still relatively young, the potential for this modality to become a differentiated and therapeutic reality is strong, such that both academic and pharmaceutical institutions are now entering this interesting area of research. In this article, we describe a broadly applicable process for identifying degrader hits based on the serine/threonine kinase TANK-binding kinase 1 (TBK1) and have generalized the key structural elements associated with degradation activities. Compound 3i is a potent hit (TBK1 DC 50 = 12 nM, D max = 96%) with excellent selectivity against a related kinase IKKε, which was further used as a chemical tool to assess TBK1 as a target in mutant K-Ras cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Comparable findings in B16 cells were observed using two additional TBK1 inhibitors, MRT67307 32 and GSK8612 33 (Extended Data Fig. 6g-h) and the TBK1-targeted proteolysis targeting chimera (TBK1 PROTAC 3i) 34 (Extended Data Fig. 6i).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [34]
In the citing paper
“It has been shown that a PROTAC’s ability to bind the target protein is not the primary determinant of whether efficient degradation occurs; rather, it has been suggested that formation of the ternary complex is limiting (i.e., the ability of the PROTAC to simultaneously bind both the target protein and the E3 ligase) 20, 22.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [22]
In the citing paper
“Similar positive outcomes could be achieved with PROTACs targeting TANK-binding kinase 1 (TBK1) [92], and ALK, where a clear correlation between efficacy in inhibiting cell proliferation and ALK driver status in different cell lines could be observed [93].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [92]
Citations
Cites
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citationCatalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citationStructural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Self-citationSelective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Self-citationOral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
The emerging complexity of protein ubiquitination
Komander, D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370937 · Cited by 821
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Self-citation
Cited by
Items 201–292 of 292
Lehmann, T., Schneider, H., Tonillo, J., Schanz, J., Schwarz, D. F., Schröter, C., Jäger, S., Kolmar, H., Hecht, S., Anderl, J., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00124 · Cited by 7
Identification of non-conventional small molecule degraders and stabilizers of squalene synthase
Hoock, J., Rossetti, C., Bilgin, M., Depta, L., Enemark‐Rasmussen, K., Christianson, J. C., & Laraia, L. (2023) · Chemical Science · doi:10.1039/d3sc04064j · Cited by 7
Exploring DCAF15 for reprogrammable targeted protein degradationPreprint
Coomar, S., & Gillingham, D. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/542506 · Cited by 7
He, M. Y., Tong, K. I., Liu, T., Hawkins, R. W., Shelton, V., Zeng, Y., Bakhtiari, M., Xiao, Y., Zheng, G., Sakhdari, A., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02325-4 · Cited by 6
Crosstalk and Prospects of TBK1 in Inflammation
Liu, H., Sheng, Q., Dan, J., & Xie, X. (2024) · Immunological Investigations · doi:10.1080/08820139.2024.2392587 · Cited by 5
Yang, J., Wang, Q.-L., Feng, G., & Zeng, M. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900210 · Cited by 5
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
Zhao, K., Zhang, J., Yang, Z., Wang, R., Shi, Y., Ji, Y., Zhang, S., & Liu, M. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s527906 · Cited by 4
The importance of controls in targeted protein degradation: Determining mechanism
Hill-Payne, B., Dilones, S., & Burslem, G. M. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.10.006 · Cited by 4
Sacco, G., Stammwitz, S., Belvisi, L., Pignataro, L., Corso, A. D., & Gennari, C. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100160 · Cited by 4
Trivalent PROTACs Enhance Protein Degradation Through Cooperativity and AvidityPreprint
Imaide, S., Riching, K. M., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N. B., Mahan, S. D., Murphy, N., Chan, K.-H., Testa, A., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13218695.v1 · Cited by 3
Developing potent and selective TBK1 molecular glue degraders for cancer immunotherapyPreprint
Caldwell, J. J., Zanon, P. R. A., Ferguson, I., Hallett, S. T., Tenev, T., Serrano-Aparicio, N., Wood, R. J. H., Khan, S., John, S. W., Wilson, R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702304 · Cited by 3
Selective degradation of TBK1 uncovers mechanistic insights into blocking ccRCC progression
Liao, C., Lyu, S., Johnson, R. L., Shang, T., Wang, X., Gildor, N., Li, S., Williams, N. S., James, L. I., Hu, L., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.03.013 · Cited by 3
Chakravarty, A., Wang, L.-N., Golden, R. P., Li, Z., Donovan, K. A., Afanzar, O., Zhang, Y., Fischer, E. S., Gray, N. S., & Yang, P. L. (2026) · Nature Communications · doi:10.1038/s41467-026-69263-w · Cited by 3
Targeting STK33: From Inhibition to Degradation
Zhong, S., & Wayne, J. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0224 · Cited by 3
Role of TBK1 Inhibition in Targeted Therapy of Cancer
Yang, X., & Liu, Z. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575271977231115062803 · Cited by 3
Testa, A., Lucas, X., Castro, G. V., Chan, K.-H., Wright, J. E., Runcie, A. C., Gadd, M. S., Harrison, W. T. A., Ko, E.-J., Fletcher, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b03833 · Cited by 3
Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
Shao, J., Yan, Y., Ding, D., Wang, D., He, Y., Pan, Y., Yan, W., Kharbanda, A., Li, H.-Y., & Huang, H. (2021) · doi:10.1101/2021.03.08.434493 · Cited by 2
A ubiquitination-mediated degradation system to target 14-3-3-binding phosphoproteins
Li, Z., Huang, X., Li, M., Chen, Y. E., Wang, Z., & Liu, L. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16318 · Cited by 2
Trivalent PROTACs Enhance Protein Degradation Through Cooperativity and AvidityPreprint
Imaide, S., Riching, K. M., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N. B., Mahan, S. D., Murphy, N., Chan, K.-H., Testa, A., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13218695 · Cited by 2
Phosphatase Signaling as a Therapeutic Strategy in Schizophrenia
Molony, L. E., & Tautz, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062822 · Cited by 2
Targeted Protein Degradation Chemical Probes
Galdeano, C., & Barril, X. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160745-00150 · Cited by 2
Hachenberg, T., Meyer, J., Sielenkämper, A. W., Kraft, W., Vogt, B., Breithardt, G., & Lawin, P. (1993) · PubMed · Cited by 2
Nguyen, K. T., Nguyen, H. H., Phùng, H. T. T., Chung, K. L., & Vu, T. Y. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2308778 · Cited by 2
Targeted Protein Degradation by Proteolysis Targeting Chimeras
Du, W. (2022) · Wiley eBooks · doi:10.1002/9781119627784.ch11 · Cited by 2
Sohbati, H., Amini, M., & Balalaie, S. (2022) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-129251 · Cited by 2
Sueron, S., Mahdizadeh, S. J., Chevet, É., Guillory, X., Porée, F., & Eriksson, L. A. (2026) · ChemMedChem · doi:10.1002/cmdc.70385 · Cited by 2
Verhoef, C. J. A., Crowe, C., Nakasone, M. A., Basté, A. D. L. C., Harzing, T., Span, N. A. S., Sathe, G. J., Demmers, L. C., Iso, K., Ottmann, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75333-w · Cited by 2
Proteolysis targeting chimeras for drug discovery from mechanistic basis to clinical translation
Badadhe, S. G., Gawali, V. B., Bhalsing, M. D., & Jangme, C. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00963-4 · Cited by 1
Novel Technologies in PROTAC Design
Jain, K., Reddy, S. C., Moode, S., Mehra, P., Tarannum, S., Patel, M., Jain, V. K., & Popli, H. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_5 · Cited by 1
Knoll, N., Somay, K., Tiwari, P. B., Deniz, E., Formen, J. S. S. K., Frye, I., Nelson, E., Wolf, C., Toretsky, J. A., & Üren, A. (2026) · Cancers · doi:10.3390/cancers18152375 · Cited by 1
Exploring linker fluorination to optimise PROTAC potency, selectivity, and physical properties
Troup, R. I. (2023) · ePrints Soton (University of Southampton) · Cited by 1
Chen, Y., Zhou, N., He, X., Su, Y., Tang, H., Wang, F., Xu, W., Chen, Z., & Guo, D. (2023) · Research Square · doi:10.21203/rs.3.rs-2739711/v1 · Cited by 1
Cossy, J., Polàk, P., & Ruer, P. C. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob01045c · Cited by 1
PROTACS- targeted protein degradation as a path to precision cancer therapeutics
Gatley, H. R., Fisher, P. B., & Das, S. K. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.001
Lowe, J. A., III (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739908982.793584562
Molecular Glues as Activators for PPI
Qi, X. (2025) · Wiley eBooks · doi:10.1002/9783527845828.ch13
Kjølbye, L. R., Pereira, G. P., Bartocci, A., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16.pr5
Kjølbye, L. R., Pereira, G. P., Bartocci, A., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16.pr4
Review: Towards design of drugs and delivery systems with the Martini coarse-grained model — R0/PR1
Kjølbye, L. R., Pereira, G. P., Bartocci, A., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16.pr1
Review: Towards design of drugs and delivery systems with the Martini coarse-grained model — R0/PR3
Kjølbye, L. R., Pereira, G. P., Bartocci, A., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16.pr3
Review: Towards design of drugs and delivery systems with the Martini coarse-grained model — R0/PR2
Kjølbye, L. R., Pereira, G. P., Bartocci, A., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16.pr2
Supplementary Data from TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss
Hu, L., Xie, H., Liu, X., Potjewyd, F., James, L. I., Wilkerson, E., Herring, L. E., Xie, L., Chen, X., Cabrera, J. C., et al. (2023) · doi:10.1158/2159-8290.22535705
Chiang, C. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737836027.793574330
BindingDB (2024) · UC San Diego · doi:10.7270/q2x352pq
BindingDB Entry 50008147: Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
BindingDB (2021) · UC San Diego · doi:10.7270/q21n84hw
Li, J. J. (2020) · Wiley eBooks · doi:10.1002/9781119607311.ch2
BindingDB (2021) · UC San Diego · doi:10.7270/q2nz8c6f
Research progress of proteolysis-targeting chimeras in viral hepatitis drug discovery
Hao, X., Wang, Y., Huang, G., Lin, C., Zhao, P., Zhi, W., Li, X., Qi, P., & Liu, P. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1810498
BindingDB Entry 50019429: STING antagonists, synthesized
BindingDB (2024) · UC San Diego · doi:10.7270/q2tf02pb
BindingDB Entry 50013121: Discovery of a PROTAC targeting ALK with in vivo activity.
BindingDB (2022) · UC San Diego · doi:10.7270/q25h7m0f
BindingDB Entry 50021665: The application of PROTAC in HDAC.
BindingDB (2025) · UC San Diego · doi:10.7270/q2474gjr
BindingDB Entry 50018797: A bibliometric analysis of PROTAC from 2001 to 2021.
BindingDB (2024) · UC San Diego · doi:10.7270/q28p64s7
BindingDB (2025) · UC San Diego · doi:10.7270/q2b85dsn
Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
Trauner, D. H., & Arp, C. J. (2020) · Synfacts · doi:10.1055/s-0040-1707494
BindingDB Entry 50019525: PROTACS: A technology with a gold rush-like atmosphere.
BindingDB (2024) · UC San Diego · doi:10.7270/q2hq4488
BindingDB (2020) · UC San Diego · doi:10.7270/q2pg1v9d
BindingDB (2023) · UC San Diego · doi:10.7270/q2vm4h9b
Structure of TBK1 and Small Molecule Inhibitors
张, 敏. (2022) · Journal of Organic Chemistry Research · doi:10.12677/jocr.2022.101002
First demonstration of benzosultam CRBN ligand-mediated PROTACs for BTK and BRD4 degradation
Park, H., Jeun, M., Choi, J. U., Bang, Y., Park, C. H., & Kim, P. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00815a
Research Strategies for Investigating Protein Ubiquitination in Lung Diseases
Zhao, Y. (2024) · CRC Press eBooks · doi:10.1201/9781003355243-10
Strategy for Lead Identification for Understudied KinasesPreprint
Drewry, D. H., Annor‐Gyamfi, J. K., Wells, C. I., Pickett, J. E., & Axtman, A. D. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14195207
BindingDB Entry 50008525: Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
BindingDB (2021) · UC San Diego · doi:10.7270/q2cn7795
Fang, H., Li, P., Gao, Q., Du, S., Gu, J., Liu, X., Peng, B., Bai, H., Zhang, C.-W., Li, L., et al. (2026) · Science China Chemistry · doi:10.1007/s11426-025-2982-3
Gechijian, L. (2018) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Kizhake, S., & Natararajan, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.18.752745
Unbiased, Target-Agnostic Platform for the Synthesis and Screening of PROTAC Libraries
Busse, A. A., Rodriguez, M., Duncan, L. M., Luo, A., Bayona, J. D., Wanigasekara, M. S. K., Rosenblatt, M. M., Posner, B. A., Kober, D. L., Deng, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02816
A Greener and Scalable Approach for the Synthesis of MRT67307 and Its AntiInflammatory Activity
Dhavaria, S., Maram, K., Priya, M. R. K., Tandon, R., & Dhiman, M. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363224613474
Bai, N. (2019) · KU ScholarWorks (University of Kansas)
Tomoshige, S., & Minoru, I. (2020) · Institutional Repositories DataBase (IRDB)
Convergent medicinal chemistry approaches against susceptible and resistant mycobacterial infections
Girardini, M. (2020) · DSpaceUnipr (University of Parma)
Li, Y., Qu, Z., Jiang, L., Chen, H., Tan, J., & Cao, X. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7096250
Toy, L. (2026) · OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) · doi:10.25593/open-fau-2637
Proteiinien kohdennettu pilkkominen lääkekehityksessä : PROTACien avulla
Tuomi, I. (2024) · UTUPub (University of Turku)
PROTAC virtual screening: A retrospective screening exercise
Ajani, H., & Schapira, M. (2019) · Figshare · doi:10.5281/zenodo.3401706
E3 ligase UHRF2 hijacks nuclear TBK1 to epigenetically repress type I interferons expression
Huang, W., Song, R., Shen, Q., Shi, Y., Wang, X., Li, N., Zhang, Q., & Cao, X. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.135125
Modification of peptides for improved membrane permeability and side chain diversity
Openy, O. J. N. (2023) · Technische Universität Dortmund Eldorado (Technische Universität Dortmund) · doi:10.17877/de290r-23840
Li, P., Liu, J., Qiao, X., Zhong, C., Liu, X., Wu, H., Zhou, Y., Huang, J., Guo, X., Wang, H., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9012405/v1
Насичені боронові похідні – інструменти створення нових зв’язків
Григоренко, О. О., & Москвіна, В. С. (2021) · eKNUTSHIR
Interferon-γ-Mediated Inflammation: To Kill or Not to Kill
Sun, N. D., & Ting, A. T. (2026) · DNA and Cell Biology · doi:10.1177/10445498261508940
Metadata
- Authors
- Crew, A. P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y. V., Hamman, B. D., Morgan, A., Ferraro, C., Siu, K., Neklesa, T. K., Winkler, J. D., Coleman, K. G., & Crews, C. M.
- Affiliations
- Arvinas (United States) (US)
- Yale University (US)
- Corresponding author
- Crew, Andrew P.
- Crews, Craig M.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-07-10
- Volume
- 61
- Issue
- 2
- Pages
- 583-598
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2735419424
- Cited by
- 257
- References
- 29
- Citations by year
- 2026: 15 · 2025: 17 · 2024: 25 · 2023: 22 · 2022: 36 · 2021: 42 · 2020: 43 · 2019: 30 · 2018: 21 · 2017: 4
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R35CA197589)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, TBK1, targeted protein degradation, VHL, serine/threonine kinase inhibitors, IKKε, bifunctional molecules
- MeSH terms
- Cell Line, Fluorescence Polarization, Humans, Mutation, Genes, ras, Structure-Activity Relationship, Molecular Structure, Protein Serine-Threonine Kinases, RNA Interference, Cell Proliferation, I-kappa B Kinase, Von Hippel-Lindau Tumor Suppressor Protein, Proteolysis, Chemistry Techniques, Synthetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.